Jens Siveke

Prof. Dr. Jens Siveke is a leading academic and clinical researcher in translational oncology at the University of Duisburg-Essen, where he serves as Head of the Translational Oncology group at the Bridge Institute for Experimental Tumor Therapy (BIT), part of the West German Cancer Center (WTZ). He is affiliated with the DKTK/DKFZ partner site in Essen and leads research at the intersection of experimental tumor biology and clinical translation.

• University: University of Duisburg-Essen
• School: Medical Faculty
• Department: Division for Solid Tumor Translational Oncology
• Research Institute: Bridge Institute for Experimental Tumor Therapy (BIT)

His research focuses on pancreatic cancer and other hard-to-treat solid tumors, leveraging preclinical models such as organoids, PDX, and GEMMs to study tumor heterogeneity, cellular plasticity, and the tumor microenvironment. He integrates molecular profiling, drug discovery, and imaging technologies to develop personalized therapeutic strategies. His work emphasizes epigenetic, immune, and metabolic targeting, with a strong focus on clinical translation.

The analysis of his recent publications reveals a consistent trajectory in advancing precision oncology through innovative model systems and biomarker development. His work spans from basic mechanisms of therapy resistance to clinical imaging and early-phase trials. Key themes include epigenetic regulation, immune evasion, microbiome influences, and theranostic imaging. He frequently publishes in top-tier journals such as Nature, Cancer Cell, and The Lancet, reflecting high-impact contributions.

Scientific contributions include:

• Discovery of progranulin-mediated immune evasion in pancreatic cancer
• Role of LAMC2 in pancreatic tumor growth
• Development of FAPI-based PET and radioligand therapy
• Mechanisms of resistance to MAPK and AKT inhibitors
• Microbiota-derived metabolites affecting chemotherapy

He leads a dynamic research team and collaborates extensively across the DKTK network and industry partners. He is involved in clinical trial design and biomarker validation, including trials like NEOLAP and NAPOLI-1. His lab develops digital platforms for patient-reported outcomes and accelerated evaluation of interventions. He mentors junior scientists and contributes to national and international oncology consortia.

His work is supported by DKTK, DFG, and other major funding bodies, enabling the development of diagnostic and therapeutic platforms for patient-relevant outcomes. He is actively engaged in future projects aiming to validate novel targets and translate findings into clinical practice using complex biological and digital ecosystems.